脱髮症的全球市场的评估:各类型，性别，不同治疗，销售，各流通管道，各地区，机会，预测(2017年～2031年)

全球脱髮市场规模预计将从 2023 年的 95.2 亿美元增至 2031 年的 186.2 亿美元，预计 2024-2031 年的复合年增长率为 8.75%。由于疾病负担的增加、脱髮研究环境的强大、人们对脱髮的认识不断提高、医疗保健系统的加强等，预计该市场将以更快的速度增长。

脱髮是一种发炎性自体免疫疾病，会促使脱髮而不留疤痕，对患者的身心健康有重大影响。脱髮的严重程度取决于脱髮的类型，但就患病率而言，斑秃是最常见的。市场推动因素包括老年人口的增加、脱髮和多囊性卵巢综合症（PCOS）等相关疾病盛行率的增加、对治疗的认识和需求的提高以及治疗的进步。儘管有这些推动因素，市场还面临诸如与脱髮治疗相关的副作用等课题，这阻碍了市场的成长。此外，从潜在候选药物中获得的可靠研究成果进一步支持未来的市场成长。

2024 年 7 月，Dermaliq Therapeutics, Inc. 宣布了 DLQ01 临床试验的统计显着数据，DLQ01 是该公司治疗雄性秃的局部候选产品。在同一项研究中，DLQ01 使目标区域的头髮数量比基线增加了 12.3%，83% 的受试者做出积极反应。本研究的终点是 6 个月研究结束时目标区域的毛髮数量、休止期与退化期比率以及皮肤安全性相对于基线的变化。这项研究是在澳洲墨尔本的辛克莱皮肤科进行的。

本报告提供全球脱髮症市场相关调查分析，提供市场规模与预测，市场动态，主要企业的形势等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 全球脱髮症市场预测(2017年～2031年)

• 市场规模的分析与预测
  • 金额
• 市场占有率的分析与预测
  • 各类型
  • 性别
  • 不同治疗
  • 各销售额
  • 各流通管道
  • 各地区
  • 市场占有率分析:各企业(金额)(前五名公司和其他 - 2023年)
• 市场地图分析(2023年)
  • 各类型
  • 性别
  • 不同治疗
  • 各销售额
  • 各流通管道
  • 各地区

第5章 北美的脱髮症市场预测(2017年～2031年)

• 市场规模的分析与预测
  • 金额
• 市场占有率的分析与预测
  • 各类型
  • 性别
  • 不同治疗
  • 各销售额
  • 各流通管道
  • 占有率:各国
• 各国的市场评估
  • 美国的脱髮症市场预测(2017年～2031年)
  • 加拿大
  • 墨西哥

第6章 欧洲的脱髮症市场预测(2017年～2031年)

• 德国
• 法国
• 义大利
• 英国
• 俄罗斯
• 荷兰
• 西班牙
• 波兰

第7章 亚太地区的脱髮症市场预测(2017年～2031年)

• 印度
• 中国
• 日本
• 澳洲
• 越南
• 韩国
• 印尼
• 菲律宾

第8章 南美的脱髮症市场预测(2017年～2031年)

• 巴西
• 阿根廷

第9章 中东·非洲的脱髮症市场预测(2017年～2031年)

• 沙乌地阿拉伯
• 阿拉伯联合大公国
• 南非
• 以色列

第10章 供需分析

第11章 价值链分析

第12章 波特的五力分析

第13章 大环境分析

第14章 价格分析

第15章 市场动态

• 推动市场要素
• 市场课题

第16章 市场趋势与发展

第17章 法规结构和革新

• 临床试验
• 法规当局的认证

第18章 专利形势

第19章 案例研究

第20章 竞争情形

• 市场前五名领导者企业的竞争矩阵
• 前五名公司的SWOT分析
• 前十大主要企业的形势
  • Janssen Global Services Inc.
  • Aclaris Therapeutics, Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Sun Pharmaceuticals Industries Limited
  • Dr. Reddy's Laboratories Ltd
  • Aurobindo Pharma
  • Viatris Inc.
  • Pfizer, Inc.
  • Eli Lilly and Company

第21章 策略性推荐

第22章 本公司相关资料，免责声明

Global alopecia market is projected to witness a CAGR of 8.75% during the forecast period 2024-2031, growing from USD 9.52 billion in 2023 to USD 18.62 billion in 2031. The market for alopecia therapeutics is anticipated to thrive at a faster pace under the influence of the growing disease burden, robust research environment around the disease, rising awareness about alopecia, and strengthening the healthcare system.

Alopecia is an inflammatory autoimmune disease that causes nonscarring hair loss that can significantly impact both the physical and psychological well-being of patients. The intensity of hair loss may vary depending on the type of alopecia; alopecia areata is the most common type of alopecia in terms of prevalence. Drivers for this market include the increasing geriatric population, rising prevalence of alopecia and related conditions like Polycystic Ovary Syndrome (PCOS), growing awareness and demand for treatments, and advancements in therapies. Despite these driving forces, the market also faces some challenges, such as side effects associated with alopecia treatment, which hinder market growth. Additionally, robust research findings from potential pharmaceutical candidates further enhance futuristic market growth.

In July 2024, Dermaliq Therapeutics, Inc. announced statistically significant topline data from a clinical trial for its topical product candidate DLQ01 for male pattern baldness. The trial showed that DLQ01 increased target area hair counts by 12.3% from baseline, with 83% of subjects responding positively. Endpoints of the study included the changes from baseline at the end of the study at six months in target area hair counts, anagen to telogen ratios, and cutaneous safety. The trial was conducted at Sinclair Dermatology, Melbourne, Australia.

High Disease Burden of Alopecia to Boost Market Demand

The population affected by alopecia conditions is steadily growing, and thus, the demand for alopecia therapeutics is also rising swiftly. The high disease burden of alopecia not only underscores the urgent need for effective treatments but also stimulates market growth through increased prevalence, significant psychosocial impacts on patients, and a robust focus on research and development. These factors collectively enhance the therapeutic landscape for alopecia, promising a dynamic future for the market. The efforts made by stakeholders such as market players, research organizations, and associations to reduce the disease burden are further providing market growth. According to the data published by the National Alopecia Areata Foundation, approximately 2% of people worldwide will experience alopecia areata at some point in their lives. In the United States, nearly 7 million people and around 160 million people globally either have or will develop alopecia areata. Currently, about 700,000 people in the United States have some form of alopecia areata.

Novel Therapy Development to Propel Market Growth

The conventional treatment options for alopecia include pharmaceutical administration through oral and topical routes and platelet-rich plasma therapy. Novel therapies have evolved in recent times which hold promising growth for the market. Researchers across the globe are involved in various research models to explore the therapeutic potential of novel therapies to stimulate hair growth and reverse hair loss. One such example is demonstrated in an article published in Advanced Materials journals in April 2024; researchers have created a new treatment to reverse hair loss caused by the autoimmune disease alopecia areata. They used a microneedle patch to painlessly target affected areas of the skin. Alopecia areata leads to hair loss when T cells mistakenly attack hair follicles. To regain control over hyperactive immune cells, researchers from Brigham and Women's Hospital and MIT delivered T cell regulators directly to the sites of hair loss to stop the autoimmune activity.

Alopecia Areata Segment to Dominate the Alopecia Market

The alopecia areata segment is poised to dominate the global alopecia market due to several key factors. As an autoimmune condition characterized by patchy hair loss, alopecia areata affects approximately a significant amount of the population. The immune response does not permanently damage hair follicles, allowing for potential regrowth, which is a characteristic feature of this type of alopecia. Genetic predisposition plays a significant role in the development of alopecia areata. Individuals with a family history of autoimmune diseases are at a higher risk. Strategic product launches at regular intervals further enhance the market share of the alopecia areata segment; for instance, in June 2023, Pfizer Inc. announced that the United States Food and Drug Administration has approved LITFULO (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. The approved recommended dose for LITFULO is 50 mg. It is the first and only treatment approved by the FDA for adolescents (12 years and above) with severe alopecia areata. LITFULO is a kinase inhibitor that inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in the hepatocellular carcinoma family of kinases.

North America Dominates Alopecia Market

North America is anticipated to emerge as the dominant region in the global alopecia market, securing a substantial market share. The region boasts a sophisticated healthcare system that provides seamless diagnosis and treatment of alopecia. Patients have access to a wide range of treatment options, including advanced therapies and personalized medicine. There is heightened awareness among healthcare professionals and the public about alopecia and available treatment options. The relatively high healthcare expenditure per capita in North America facilitates increased spending on alopecia treatment. This allows patients to access a wide range of treatment options, contributing to the region's dominant market position. As the prevalence of alopecia continues to rise and new treatment options emerge coupled with USFDA approvals, North America is poised to maintain its dominance in the coming years. In July 2024, Sun Pharmaceutical Industries Limited received USFDA approval for LEQSELVI (deuruxolitinib) used for treating an autoimmune disorder in adults. LEQSELVI is a new, twice-daily oral Janus Kinase (JAK) inhibitor that disrupts the pathways involved in hair loss.

Future Market Scenario (2024-2031F)

Rising awareness among common people about alopecia is anticipated to drive the global alopecia market in the future. Several organizations across the globe are working in favor of alopecia awareness and advocacy. Some of these organizations include the National Alopecia Areata Foundation, Alopecia UK, Pfizer Inc., Canadian Alopecia Areata Foundation, Scarring Alopecia Foundation, American Hair Loss Association, Australia Alopecia Areata Foundation, and many more.

In 1986, the National Alopecia Areata Foundation declared September Alopecia Awareness Month, and since then, several awareness campaigns, marches, donation drives, and other initiatives to enhance awareness about alopecia and its treatment options are observed every year. Such initiatives from stakeholder organizations are anticipated to improve the diagnosis rate and thus drive the future demand for alopecia treatment.

Key Players Landscape and Outlook

The alopecia market comprises several market players ranging from small-cap to large-cap companies. Although the greater share of the market is covered by giants like Eli Lilly and Company and Sun Pharmaceutical Industries Limited, the smaller players, startups, are mainly invested in targeted therapies and treatment development, including medical devices like laser caps. The trend of acquisitions and collaborative business has been observed in the market in recent times.

For instance, in September 2024, Eli Lilly and Company, in collaboration with EVA Pharma (a subsidiary of Armanious Group), announced an agreement to increase access to baricitinib for an estimated 20,000 individuals across 49 low- to middle-income countries in Africa by 2030. Baricitinib, discovered by Incyte Corporation and licensed to Lilly, is used in the treatment of rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19. This collaboration is part of the Lilly 30x30 initiative, which aims to enhance access to quality healthcare for 30 million people living in resource-limited settings annually by 2030.

In March 2023, Sun Pharmaceutical Industries Limited completed its acquisition of Concert Pharmaceuticals, Inc. This company is a late-stage clinical biopharmaceutical company developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor for potentially treating adult patients with moderate to severe alopecia areata.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Alopecia Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Alopecia Areata
    • 4.2.1.2. Cicatricial Alopecia
    • 4.2.1.3. Traction Alopecia
    • 4.2.1.4. Alopecia Totalis
    • 4.2.1.5. Androgenetic Alopecia
    • 4.2.1.6. Alopecia Universalis
    • 4.2.1.7. Others
  • 4.2.2. By Gender
    • 4.2.2.1. Male
    • 4.2.2.2. Female
  • 4.2.3. By Treatment
    • 4.2.3.1. Pharmaceuticals
      • 4.2.3.1.1. Topical
        • 4.2.3.1.1.1. Minoxidil
        • 4.2.3.1.1.2. Betamethasone Dipropionate
        • 4.2.3.1.1.3. Fluocinolone Acetonide
        • 4.2.3.1.1.4. Finasteride
        • 4.2.3.1.1.5. Others
      • 4.2.3.1.2. Oral
        • 4.2.3.1.2.1. Minoxidil
        • 4.2.3.1.2.2. Finasteride
        • 4.2.3.1.2.3. Corticosteroids
        • 4.2.3.1.2.4. Others
    • 4.2.3.2. Devices
      • 4.2.3.2.1. Laser Cap
      • 4.2.3.2.2. Laser Comb
      • 4.2.3.2.3. Laser Helmet
    • 4.2.3.3. Platelet-Rich Plasma Therapy
  • 4.2.4. By Sales
    • 4.2.4.1. Prescription
    • 4.2.4.2. Over The Counter
  • 4.2.5. By Distribution Channel
    • 4.2.5.1. Homecare Settings
    • 4.2.5.2. Dermatology Clinics
  • 4.2.6. By Region
    • 4.2.6.1. North America
    • 4.2.6.2. Europe
    • 4.2.6.3. Asia-Pacific
    • 4.2.6.4. South America
    • 4.2.6.5. Middle East and Africa
  • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Type
  • 4.3.2. By Gender
  • 4.3.3. By Treatment
  • 4.3.4. By Sales
  • 4.3.5. By Distribution Channel
  • 4.3.6. By Region

5. North America Alopecia Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Alopecia Areata
    • 5.2.1.2. Cicatricial Alopecia
    • 5.2.1.3. Traction Alopecia
    • 5.2.1.4. Alopecia Totalis
    • 5.2.1.5. Androgenetic Alopecia
    • 5.2.1.6. Alopecia Universalis
    • 5.2.1.7. Others
  • 5.2.2. By Gender
    • 5.2.2.1. Male
    • 5.2.2.2. Female
  • 5.2.3. By Treatment
    • 5.2.3.1. Pharmaceuticals
      • 5.2.3.1.1. Topical
        • 5.2.3.1.1.1. Minoxidil
        • 5.2.3.1.1.2. Betamethasone Dipropionate
        • 5.2.3.1.1.3. Fluocinolone Acetonide
        • 5.2.3.1.1.4. Finasteride
        • 5.2.3.1.1.5. Others
      • 5.2.3.1.2. Oral
        • 5.2.3.1.2.1. Minoxidil
        • 5.2.3.1.2.2. Finasteride
        • 5.2.3.1.2.3. Corticosteroids
        • 5.2.3.1.2.4. Others
    • 5.2.3.2. Devices
      • 5.2.3.2.1. Laser Cap
      • 5.2.3.2.2. Laser Comb
      • 5.2.3.2.3. Laser Helmet
    • 5.2.3.3. Platelet-Rich Plasma Therapy
  • 5.2.4. By Sales
    • 5.2.4.1. Prescription
    • 5.2.4.2. Over The Counter
  • 5.2.5. By Distribution Channel
    • 5.2.5.1. Homecare Settings
    • 5.2.5.2. Dermatology Clinics
  • 5.2.6. By Country Share
    • 5.2.6.1. United States
    • 5.2.6.2. Canada
    • 5.2.6.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Alopecia Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Type
        • 5.3.1.2.1.1. Alopecia Areata
        • 5.3.1.2.1.2. Cicatricial Alopecia
        • 5.3.1.2.1.3. Traction Alopecia
        • 5.3.1.2.1.4. Alopecia Totalis
        • 5.3.1.2.1.5. Androgenetic Alopecia
        • 5.3.1.2.1.6. Alopecia Universalis
        • 5.3.1.2.1.7. Others
      • 5.3.1.2.2. By Gender
        • 5.3.1.2.2.1. Male
        • 5.3.1.2.2.2. Female
      • 5.3.1.2.3. By Treatment
        • 5.3.1.2.3.1. Pharmaceuticals
        • 5.3.1.2.3.1.1. Topical
        • 5.3.1.2.3.1.1.1. Minoxidil
        • 5.3.1.2.3.1.1.2. Betamethasone Dipropionate
        • 5.3.1.2.3.1.1.3. Fluocinolone Acetonide
        • 5.3.1.2.3.1.1.4. Finasteride
        • 5.3.1.2.3.1.1.5. Others
        • 5.3.1.2.3.1.2. Oral
        • 5.3.1.2.3.1.2.1. Minoxidil
        • 5.3.1.2.3.1.2.2. Finasteride
        • 5.3.1.2.3.1.2.3. Corticosteroids
        • 5.3.1.2.3.1.2.4. Others
        • 5.3.1.2.3.2. Devices
        • 5.3.1.2.3.2.1. Laser Cap
        • 5.3.1.2.3.2.2. Laser Comb
        • 5.3.1.2.3.2.3. Laser Helmet
        • 5.3.1.2.3.3. Platelet-Rich Plasma Therapy
      • 5.3.1.2.4. By Sales
        • 5.3.1.2.4.1. Prescription
        • 5.3.1.2.4.2. Over The Counter
      • 5.3.1.2.5. By Distribution Channel
        • 5.3.1.2.5.1. Homecare Settings
        • 5.3.1.2.5.2. Dermatology Clinics
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Alopecia Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Alopecia Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Alopecia Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Alopecia Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Janssen Global Services Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. Aclaris Therapeutics, Inc.
  • 20.3.3. Merck & Co., Inc.
  • 20.3.4. GlaxoSmithKline plc
  • 20.3.5. Sun Pharmaceuticals Industries Limited
  • 20.3.6. Dr. Reddy's Laboratories Ltd
  • 20.3.7. Aurobindo Pharma
  • 20.3.8. Viatris Inc.
  • 20.3.9. Pfizer, Inc.
  • 20.3.10. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Alopecia Market Share (%), By Type, 2017-2031F
• Figure 3. Global Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 4. Global Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 5. Global Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 6. Global Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 7. Global Alopecia Market Share (%), By Region, 2017-2031F
• Figure 8. North America Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 9. North America Alopecia Market Share (%), By Type, 2017-2031F
• Figure 10. North America Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 11. North America Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 12. North America Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 13. North America Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 14. North America Alopecia Market Share (%), By Country, 2017-2031F
• Figure 15. United States Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 16. United States Alopecia Market Share (%), By Type, 2017-2031F
• Figure 17. United States Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 18. United States Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 19. United States Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 20. United States Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 21. Canada Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 22. Canada Alopecia Market Share (%), By Type, 2017-2031F
• Figure 23. Canada Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 24. Canada Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 25. Canada Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 26. Canada Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 27. Mexico Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 28. Mexico Alopecia Market Share (%), By Type, 2017-2031F
• Figure 29. Mexico Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 30. Mexico Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 31. Mexico Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 32. Mexico Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 33. Europe Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 34. Europe Alopecia Market Share (%), By Type, 2017-2031F
• Figure 35. Europe Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 36. Europe Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 37. Europe Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 38. Europe Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 39. Europe Alopecia Market Share (%), By Country, 2017-2031F
• Figure 40. Germany Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 41. Germany Alopecia Market Share (%), By Type, 2017-2031F
• Figure 42. Germany Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 43. Germany Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 44. Germany Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 45. Germany Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 46. France Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 47. France Alopecia Market Share (%), By Type, 2017-2031F
• Figure 48. France Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 49. France Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 50. France Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 51. France Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 52. Italy Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Italy Alopecia Market Share (%), By Type, 2017-2031F
• Figure 54. Italy Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 55. Italy Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 56. Italy Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 57. Italy Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 58. United Kingdom Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 59. United Kingdom Alopecia Market Share (%), By Type, 2017-2031F
• Figure 60. United Kingdom Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 61. United Kingdom Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 62. United Kingdom Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 63. United Kingdom Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 64. Russia Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 65. Russia Alopecia Market Share (%), By Type, 2017-2031F
• Figure 66. Russia Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 67. Russia Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 68. Russia Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 69. Russia Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 70. Netherlands Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 71. Netherlands Alopecia Market Share (%), By Type, 2017-2031F
• Figure 72. Netherlands Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 73. Netherlands Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 74. Netherlands Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 75. Netherlands Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 76. Spain Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 77. Spain Alopecia Market Share (%), By Type, 2017-2031F
• Figure 78. Spain Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 79. Spain Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 80. Spain Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 81. Spain Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 82. Turkey Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 83. Turkey Alopecia Market Share (%), By Type, 2017-2031F
• Figure 84. Turkey Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 85. Turkey Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 86. Turkey Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 87. Turkey Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 88. Poland Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 89. Poland Alopecia Market Share (%), By Type, 2017-2031F
• Figure 90. Poland Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 91. Poland Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 92. Poland Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 93. Poland Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 94. South America Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 95. South America Alopecia Market Share (%), By Type, 2017-2031F
• Figure 96. South America Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 97. South America Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 98. South America Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 99. South America Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 100. South America Alopecia Market Share (%), By Country, 2017-2031F
• Figure 101. Brazil Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 102. Brazil Alopecia Market Share (%), By Type, 2017-2031F
• Figure 103. Brazil Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 104. Brazil Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 105. Brazil Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 106. Brazil Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 107. Argentina Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 108. Argentina Alopecia Market Share (%), By Type, 2017-2031F
• Figure 109. Argentina Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 110. Argentina Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 111. Argentina Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 112. Argentina Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 113. Asia-Pacific Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 114. Asia-Pacific Alopecia Market Share (%), By Type, 2017-2031F
• Figure 115. Asia-Pacific Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 116. Asia-Pacific Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 117. Asia-Pacific Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 118. Asia-Pacific Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 119. Asia-Pacific Alopecia Market Share (%), By Country, 2017-2031F
• Figure 120. India Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 121. India Alopecia Market Share (%), By Type, 2017-2031F
• Figure 122. India Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 123. India Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 124. India Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 125. India Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 126. China Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 127. China Alopecia Market Share (%), By Type, 2017-2031F
• Figure 128. China Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 129. China Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 130. China Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 131. China Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 132. Japan Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 133. Japan Alopecia Market Share (%), By Type, 2017-2031F
• Figure 134. Japan Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 135. Japan Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 136. Japan Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 137. Japan Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 138. Australia Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 139. Australia Alopecia Market Share (%), By Type, 2017-2031F
• Figure 140. Australia Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 141. Australia Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 142. Australia Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 143. Australia Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 144. Vietnam Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 145. Vietnam Alopecia Market Share (%), By Type, 2017-2031F
• Figure 146. Vietnam Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 147. Vietnam Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 148. Vietnam Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 149. Vietnam Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 150. South Korea Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 151. South Korea Alopecia Market Share (%), By Type, 2017-2031F
• Figure 152. South Korea Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 153. South Korea Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 154. South Korea Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 155. South Korea Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 156. Indonesia Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 157. Indonesia Alopecia Market Share (%), By Type, 2017-2031F
• Figure 158. Indonesia Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 159. Indonesia Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 160. Indonesia Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 161. Indonesia Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 162. Philippines Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 163. Philippines Alopecia Market Share (%), By Type, 2017-2031F
• Figure 164. Philippines Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 165. Philippines Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 166. Philippines Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 167. Philippines Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 168. Middle East & Africa Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 169. Middle East & Africa Alopecia Market Share (%), By Type, 2017-2031F
• Figure 170. Middle East & Africa Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 171. Middle East & Africa Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 172. Middle East & Africa Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 173. Middle East & Africa Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 174. Middle East & Africa Alopecia Market Share (%), By Country, 2017-2031F
• Figure 175. Saudi Arabia Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 176. Saudi Arabia Alopecia Market Share (%), By Type, 2017-2031F
• Figure 177. Saudi Arabia Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 178. Saudi Arabia Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 179. Saudi Arabia Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 180. Saudi Arabia Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 181. UAE Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 182. UAE Alopecia Market Share (%), By Type, 2017-2031F
• Figure 183. UAE Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 184. UAE Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 185. UAE Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 186. UAE Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 187. South Africa Alopecia Market, By Value, In USD Billion, 2017-2031F
• Figure 188. South Africa Alopecia Market Share (%), By Type, 2017-2031F
• Figure 189. South Africa Alopecia Market Share (%), By Gender, 2017-2031F
• Figure 190. South Africa Alopecia Market Share (%), By Treatment, 2017-2031F
• Figure 191. South Africa Alopecia Market Share (%), By Sales, 2017-2031F
• Figure 192. South Africa Alopecia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 194. By Gender Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 195. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 196. By Sales Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023